Graefen M - Search Results

1

Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.

Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T, Lughezzani G, Lista G, Larcher A, Bini V, Cestari A, Buffi N, Graefen M, Bosset O, Le Corvoisier P, Breda A, de la Torre P, Fowler L, Roux J, Guazzoni G. Lazzeri M, et al. Among authors: graefen m. BJU Int. 2013 Aug;112(3):313-21. doi: 10.1111/bju.12217. BJU Int. 2013. PMID: 23826841

2

Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.

Haese A, Graefen M, Noldus J, Hammerer P, Huland E, Huland H. Haese A, et al. Among authors: graefen m. J Urol. 1997 Dec;158(6):2188-92. doi: 10.1016/s0022-5347(01)68192-8. J Urol. 1997. PMID: 9366341

3

Incidence of positive surgical margins after biopsy-selected nerve-sparing radical prostatectomy.

Graefen M, Hammerer P, Michl U, Noldus J, Haese A, Henke RP, Huland E, Huland H. Graefen M, et al. Urology. 1998 Mar;51(3):437-42. doi: 10.1016/s0090-4295(97)00608-0. Urology. 1998. PMID: 9510349

4

Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.

Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H. Haese A, et al. Among authors: graefen m. J Urol. 1999 Apr;161(4):1206-11. J Urol. 1999. PMID: 10081870 Clinical Trial.

5

Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.

Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer P, Fernandez S, Conrad S, Henke R, Huland E, Huland H. Graefen M, et al. Eur Urol. 1999;36(1):21-30. doi: 10.1159/000019922. Eur Urol. 1999. PMID: 10364651

6

Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure.

Haese A, Huland E, Graefen M, Huland H. Haese A, et al. Among authors: graefen m. Anticancer Res. 1999 Jul-Aug;19(4A):2641-4. Anticancer Res. 1999. PMID: 10470210

7

[Prognostic markers for prostate cancer].

Graefen M, Hammerer P, Noldus J, Haese A, Pichelmeier U, Erbersdobler A, Henke H, Conrad S, Fernandez S, Huland H. Graefen M, et al. Urologe A. 2000 Jan;39(1):14-21. doi: 10.1007/s001200050004. Urologe A. 2000. PMID: 10663191 Review. German.

8

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.

Haese A, Becker C, Noldus J, Graefen M, Huland E, Huland H, Lilja H. Haese A, et al. Among authors: graefen m. J Urol. 2000 May;163(5):1491-7. doi: 10.1016/s0022-5347(05)67649-5. J Urol. 2000. PMID: 10751864

9

Stage migration in clinically localized prostate cancer.

Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H. Noldus J, et al. Among authors: graefen m. Eur Urol. 2000 Jul;38(1):74-8. doi: 10.1159/000020255. Eur Urol. 2000. PMID: 10859445

10

A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy.

Graefen M, Haese A, Pichlmeier U, Hammerer PG, Noldus J, Butz K, Erbersdobler A, Henke RP, Michl U, Fernandez S, Huland H. Graefen M, et al. J Urol. 2001 Mar;165(3):857-63. J Urol. 2001. PMID: 11176486

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

926 results

Search Page